SITE015-0198

SITE015 (POL) › SITE015-0198

SITE015-0198

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-04-21

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-05 (study day 123); relationship: not assessed

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-02 (study day 120); relationship: NOT RELATED

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 68); relationship: NOT RELATED

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 56); relationship: NOT RELATED

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 28); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.